OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
Concurrent with this announcement, the Company announced that it has submitted End of Phase 2 Meeting and Breakthrough Therapy Designation (BTD) requests to FDA based on the positive Type D Meeting feedback. The End of Phase 2 Meeting is expected to occur in the third quarter of 2025. This is in alignment with the company's overall regulatory strategy and timelines.
'We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ,' said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. 'Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting.'
OST-HER2 has received Rare Pediatric Disease Designation (RPDD) for osteosarcoma from the US FDA, and if it receives a conditional BLA via Accelerated Review prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent PRV sale occurred in June 2025, valued at $160 million.
The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59%. 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30%. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million.
OST-HER2, an immunotherapy for osteosarcoma that uses a HER2-bioengineered form of the bacterium Listeria monocytogenes to trigger a strong immune response against HER2-expressing cancer cells, is featured in the movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. The movie is available via streaming on PBS' website.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
13 minutes ago
- Boston Globe
State OK's premiums for six health plans but sends two back to drawing board
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up A logo sign outside of the headquarters of Sarepta Therapeutics, Inc, in Cambridge. TRIPPLAAR KRISTOFFER/SIPA/Sipa USA via AP Advertisement BIOTECH Amid 'unwinnable' FDA fight, analyst cuts estimate of Sarepta shares to $0 Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, according to analysts at HC Wainwright & Co. LLC. Analysts led by Mitchell S. Kapoor on Monday slashed their price target on the stock to $0 — a rare move — from $10, while maintaining a sell recommendation. The cut comes as the drugmaker refused to voluntarily pause shipments of its lead therapy following a request by the US Food and Drug Administration after three deaths were linked to the company's gene therapies. 'We view this battle with the gatekeeper US regulatory agency as unwinnable,' Kapoor wrote in a note to clients. 'Since the request for voluntary action was likely a courtesy, we expect the FDA to ultimately require removal of Elevidys from the market.' Kapoor added that 'in the absence of future Elevidys revenues, we see no intrinsic value left in SRPT shares.' Representatives of Sarepta did not immediately respond to a Bloomberg News request for comment. Sarepta's issues with the FDA stem from reports of three patient deaths following the use of its gene therapies. Two teenage boys died of acute liver failure in recent months after taking Elevidys for the treatment of Duchenne muscular dystrophy, a muscle-wasting disease. Last week, the company said that a 51-year-old patient died of acute liver failure in June in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy. The FDA on Friday said it placed a hold on gene therapy clinical trials for that specific muscle disease. — BLOOMBERG NEWS Advertisement FINANCE Not just checking and savings but investment accounts are boosting cash in Americans' hands New research finds that more Americans are shifting their money from checking and savings accounts into financial vehicles that pay an investment income — a trend that helps to explain the resilience of the US economy after a bout of Advertisement A container ship at the Port of Oakland in Oakland, Calif. Ben Margot/Associated Press ECONOMY Key gauge of shipping slows for second straight month The number of shipping containers carrying imports to the United States fell for a second straight month, a private gauge showed, putting the economic indicator on course for one of the sharpest year-on-year reversals on record as President Trump's tariffs disrupt purchases of goods from abroad. Inbound container volume fell 7.9 percent in June from a year before, after a 6.6 percent drop in May, veteran industry analyst John McCown wrote in a monthly report Sunday based on the 10 largest US ports. The declines more than wiped out a nearly 10 percent increase tied to inventory front-loading in April, and left the second quarter down 1.8 percent from a year earlier. 'The downward turn in 2025 will be due to tariffs and unfortunately there is nothing at present that suggests it will be short-lived,' McCown wrote. McCown said he was only aware of two periods of annual volume declines — during the global financial crisis and the pandemic — and both were short-term slumps. He estimated that a 25 percent reduction in US container volumes is 'readily possible' and would translate 'directly into a $510 billion reduction in annual commerce for the US.' The total value of goods in containers moving through US ports last year was $2.2 trillion, according to McCown's data. — BLOOMBERG NEWS Advertisement FEDERAL BUDGET CBO projects 'Big Beautiful Bill' will boost deficits by $3.4 trillion President Trump's recently enacted tax and spending law will add $3.4 trillion to US deficits over a decade and leave millions without health care coverage, according to a new estimate from the nonpartisan Congressional Budget Office. The CBO score for the law, released Monday, reflects a $4.5 trillion decrease in revenues and a $1.1 trillion decline in spending through 2034, relative to a current-law baseline. The new analysis doesn't incorporate so-called dynamic effects, such as the impact on growth or interest rates over time that the legislation's measures might have. Trump signed the 'One Big Beautiful Bill' into law on July 4 after months of negotiations with congressional Republicans. Encompassing much of Trump's economic agenda, it permanently extends his 2017 income-tax cuts and some breaks for businesses, lifts the cap on federal deductions for state and local taxes, and eliminates taxes on tips and overtime on a temporary basis, among other provisions. Passage of the law triggered warnings from some economists and investors about a widening of America's budget shortfall — already large by historical standards — that could push borrowing costs and inflation up. The Trump administration points to record collections from the tariffs he's imposed on most US imports this year, saying that revenue will help fill the gap. A number of spending cuts were included in the tax law in an effort to reduce deficits and offset the cost, including to Medicaid, which provides health insurance for low-income people. — BLOOMBERG NEWS Advertisement
Business Wire
13 minutes ago
- Business Wire
Asbury Automotive Group Completes Acquisition of Herb Chambers Dealerships
DULUTH, Ga.--(BUSINESS WIRE)--Asbury Automotive Group, Inc. (NYSE: ABG) (the 'Company'), one of the largest automotive retail and service companies in the U.S., has completed the acquisition of The Herb Chambers Companies (HCC), the sixteenth largest by revenue privately-owned dealership group in the country. 'We're thrilled to complete the acquisition of The Herb Chambers Companies' assets and operations,' said David Hult, Asbury's President & CEO. 'Herb redefined the car-buying experience in New England, making 'Herb Chambers' a household name, synonymous with reliability and service. The HCC team is well known for its guest-centric focus and community involvement, and we are proud to welcome the team to the Asbury family.' 'Over the past decade, I have been approached by several companies interested in acquiring my organization. Throughout it all, the opportunity and well-being of the Chambers team remained my top priority. Without question, Asbury stood out as the ideal steward. Their leadership – especially under David Hult – is, without a doubt, the best in the industry,' said Herb Chambers, founder of The Herb Chambers Companies. This acquisition further diversifies Asbury's geographic mix with entry into the Northeastern United States. The purchase of this flagship New England Region company is one of the most sizable in U.S. automotive retail history, representing $3.2 billion in revenue in 2024, and includes 33 dealerships, 52 franchises, and three collision centers. The Herb Chambers Companies sold approximately 50,000 new and used vehicles during the year ended December 31, 2024. The aggregate net purchase price was $1.45 billion, which includes $750 million for goodwill, approximately $610 million for the real estate and leasehold improvements, and approximately $85 million for new vehicles, used vehicles, service loaner vehicles, fixed assets, parts and supplies, which is net of non-manufacturer floorplan of $375 million. Asbury primarily funded the acquisition with a combination of credit facility capacity, mortgage proceeds and cash. For additional information, please see the Form 8-K that will be filed in connection with this transaction. Advisors Jones Day and Hill Ward Henderson served as legal counsel, Baker Tilly served as the transaction advisory firm, and BofA Securities served as financial advisor to Asbury; Wells Fargo served as lead for the syndicated mortgage facility. Stephens Inc. served as financial advisor and Simpson Thacher and WilmerHale served as legal counsel to HCC. About The Herb Chambers Companies Founded in 1985, The Herb Chambers Companies is one of the nation's largest private auto dealership groups and one of the leading automotive retailers in the New England region. HCC employs more than 2,200 people in locations throughout Massachusetts and Rhode Island, with most of its dealerships located in and around Boston. Herb Chambers is consistently named as one of the Boston Globe's "Top Places to Work." About Asbury Automotive Group, Inc Asbury Automotive Group, Inc. (NYSE: ABG), a Fortune 500 company headquartered in Duluth, GA, is one of the largest automotive retailers in the U.S. In late 2020, Asbury embarked on a multi-year plan to increase revenue and profitability strategically through organic operations, acquisitive growth and innovative technologies, with its guest-centric approach as Asbury's constant North Star. As of June 30, 2025, Asbury operated 145 new vehicle dealerships, consisting of 189 franchises and representing 31 domestic and foreign brands of vehicles. Asbury also operates Total Care Auto, Powered by Landcar, a leading provider of service contracts and other vehicle protection products, and 37 collision repair centers. Asbury offers an extensive range of automotive products and services, including new and used vehicles; parts and service, which includes vehicle repair and maintenance services, replacement parts and collision repair services; and finance and insurance products, including arranging vehicle financing through third parties and aftermarket products, such as extended service contracts, guaranteed asset protection debt cancellation, and prepaid maintenance. Asbury is recognized as one of America's Fastest Growing Companies 2024 by the Financial Times and the Company is listed in World's Most Trustworthy Companies 2024 by Newsweek. For additional information, visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical fact, and may include statements relating to goals, plans, objectives, beliefs, expectations and assumptions regarding the expected benefits of the recently completed acquisition of the Herb Chambers dealerships and performance, integration plans and expected synergies from the acquisition. The following are some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including: risks related to our failure to realize the benefits expected from the acquisition; failure to promptly and effectively integrate the acquisition; disruption of management time from ongoing business operations due to the integration activities related to the acquisition; identification and remediation of insufficient control activities of the acquired business; the effect of the acquisition on the ability of Asbury to retain and hire key personnel and maintain relationships with suppliers; our ability to execute our business strategy; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2025 and subsequent filings. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Business Wire
13 minutes ago
- Business Wire
NRG Energy, Inc. to Report Second Quarter 2025 Financial Results on August 6, 2025
HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE:NRG) plans to report its second quarter 2025 financial results on Wednesday, August 6, 2025. Management will present the results during a conference call and webcast at 9:00 a.m. EST (8:00 a.m. CST). The company will issue a press release regarding the second quarter 2025 financial results prior to the conference call, and it will be available on the NRG website at The live webcast and presentation materials can be accessed at by clicking the 'presentations and webcasts' link. A replay of the webcast will be available on the site for those unable to listen in real time. About NRG NRG Energy, Inc. is leading the future of energy—now. Our solutions power a smarter, brighter future by helping customers achieve today's goals while solving for the challenges of tomorrow. Every day, we deliver innovative natural gas, electricity, and smart home solutions to customers large and small across North America. Visit for more information, and connect with us on Facebook, Instagram, LinkedIn, and X.
